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TNF-a Downregulates Filaggrin and Loricrin through
c-Jun N-terminal Kinase: Role for TNF-a Antagonists
to Improve Skin Barrier
Byung Eui Kim1, Michael D. Howell1,2, Emma Guttman3,4, Patricia M. Gilleaudeau3, Irma R. Cardinale3,
Mark Boguniewicz1,2, James G. Krueger3 and Donald Y.M. Leung1,2
Filaggrin (FLG), loricrin (LOR), and involucrin are important epidermal barrier proteins. As psoriasis is
characterized by overexpression of tumor necrosis factor-a (TNF-a) and impaired skin barrier, we investigated
the expression of skin barrier proteins in psoriasis patients and whether their expression was modulated by
TNF-a. The expression of FLG and LOR was found to be decreased in lesional and non-lesional skin of psoriasis
patients. A correlation was found between the expression of TNF-a and epidermal barrier proteins in psoriasis.
TNF-a was found to modulate the expression of FLG and LOR via a c-Jun N-terminal kinase-dependent pathway.
Importantly, we report that clinical treatment of psoriasis patients with a TNF-a antagonist results in significant
enhancement of epidermal barrier protein expression. Our current study suggests that TNF inhibits barrier
protein expression, and TNF-a antagonists may contribute to clinical improvement in patients with psoriasis by
improving barrier protein expression.
Journal of Investigative Dermatology (2011) 131, 1272–1279; doi:10.1038/jid.2011.24; published online 24 February 2011
INTRODUCTION
The epidermis provides an important physical barrier against
the environment. Filaggrin (FLG), loricrin (LOR), and
involucrin (IVL) are major proteins that have an important
role in formation of the epidermal skin barrier (Kalinin et al.,
2001; Candi et al., 2005). FLG aggregates keratin filaments
and provides a cytoskeleton for the cornified envelope (Candi
et al., 2005). LOR is initially expressed in the granular layer
and comprises 70% of the total protein mass of the cornified
layer (Kalinin et al., 2001; Candi et al., 2005). IVL is an early
component in the assembly of cornified envelope and
provides a scaffold for cornified envelope (Candi et al.,
2005).
Psoriasis is a common chronic inflammatory skin disease
and is characterized by an impaired skin barrier (Huffmeier
et al., 2007; Proksch et al., 2008). The mechanism for
reduced skin barrier function in psoriasis is not known.
Tumor necrosis factor-a (TNF-a) is overexpressed in the
epidermis of psoriasis skin (Kristensen et al., 1993; Ettehadi
et al., 1994) and has a pivotal role in the pathogenesis of
psoriasis, as many TNF-a-regulated genes are overexpressed
in psoriasis and TNF-a antagonists are highly effective
therapeutic agents in most patients (Nickoloff et al., 1991;
Richardson and Gelfand, 2008). TNF-a was functionally
linked to the IL-23/Th17 pathway in psoriasis by its ability to
activate myeloid dendritic cells (Zaba et al., 2007, 2009).
This study was conducted to determine whether overexpres-
sion of TNF-a in psoriasis may contribute to a deficiency of
epidermal barrier proteins.
RESULTS
Deficiency of FLG and LOR in psoriasis skin
We initially determined gene expression of FLG and LOR in
skin biopsies from normal subjects and in patients with
psoriasis. Using real-time RT-PCR, we found that the gene
expression of FLG is significantly decreased in lesional
(7.99±2.00 ng FLG per ng of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH); Po0.001) and non-lesional
(18.04±3.90 ng; Po0.01) skin from psoriasis patients, as
compared with skin from normal subjects (45.06±7.78 ng;
Figure 1a). In addition, FLG gene expression was significantly
decreased in lesional psoriasis skin compared with non-
lesional psoriasis skin (Po0.05). LOR gene expression
was also significantly decreased in lesional (4.60±1.72 ng
LOR per ng of GAPDH; Po0.001) and non-lesional
(8.41±2.21 ng; Po0.01) skin from psoriasis patients
compared with skin from normal subjects (27.70±6.08 ng;
Figure 1b). However, the gene expression of IVL is not
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decreased in skin from psoriasis patients (data not shown).
This was confirmed at the protein level using immunostaining
(Figure 1c and d). The composite data for FLG and LOR
staining in all samples are shown in Figure 1e and f. The
staining intensity of FLG and LOR is significantly decreased in
lesional (FLG: Po0.001; LOR: Po0.01) and non-lesional
(FLG: Po0.05) psoriasis skin, as compared with skin from
normal subjects. In addition, the staining intensity of LOR in
lesional psoriasis skin was significantly decreased compared
with non-lesional psoriasis skin (Po0.05).
TNF-a inhibits expression of FLG and LOR
Psoriasis is characterized by overexpression of TNF-a
(Kristensen et al., 1993; Ettehadi et al., 1994) and impaired
skin barrier (Huffmeier et al., 2007; Proksch et al., 2008).
Therefore, we examined whether TNF-a modulates the
expression of FLG, LOR, and IVL. We differentiated primary
human keratinocytes (KCs) with 1.3mmol l1 CaCl2 for 5
days, and then the KCs were incubated with various
concentrations of TNF-a for 24 hours. The gene expression
of FLG was significantly inhibited by TNF-a with
concentration as low as 5 ngml1 (3.06±0.48 ng FLG per
ng of GAPDH; Po0.05) compared with media alone
(5.36±0.07 ng; Figure 2a). Similarly, LOR gene expression
was significantly inhibited by TNF-a with concentrations as
low as 2 ngml1 compared with media alone (data not
shown). However, IVL gene expression was not modulated
by TNF-a (data not shown), suggesting that TNF-a does not
have a global effect on epidermal proteins.
To further understand the modulation of TNF-a on FLG
and LOR, human primary KCs were pre-incubated with a
TNF-a-neutralizing antibody (Ab) before TNF-a stimulation.
We demonstrated that FLG gene expression was not
significantly decreased in the KCs treated with a TNF-a-
neutralizing Ab (4.39±0.15 ng FLG per ng of GAPDH;
Po0.001), as compared with the untreated KCs
(2.09±0.16 ng; Figure 2b). Similarly, LOR gene expression
was not significantly decreased in the KCs pre-treated with a
TNF-a-neutralizing Ab, as compared with the untreated KCs
(data not shown).
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Figure 1. Expression of filaggrin (FLG) and loricrin (LOR) in the skin from normal subjects and patients with psoriasis. RNA was isolated from the skin of
normal subjects and patients with psoriasis. The gene expression FLG (a) and LOR (b) was evaluated using real-time RT-PCR. (c, d) Representative paraffin-
embedded skin biopsies from normal subjects (n¼10) and patients with psoriasis (n¼9) stained for FLG (c) and LOR (d) are shown. Images were collected at
400 magnification. (e, f) The intensities of the staining for FLG (e) and LOR (f) were graded visually on a scale from 0 (no staining) to 5 (the most intense
staining). The scale bar represents 50mm. *Po0.05; **Po0.01; ***Po0.001. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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The effects of TNF a, as compared with Th2 cytokines,
on barrier proteins differ
Th2 cytokines have previously been reported to down-
regulate expression of FLG, LOR, and IVL (Howell et al.,
2007; Kim et al., 2008). To determine whether the mechan-
ism for TNF-a differs from effects of Th2 cytokines on barrier
proteins, we examined the effects of Th2 cytokines and
TNF-a on gene expression of FLG, LOR, and IVL. Primary KCs
were treated with Th2 cytokines or TNF-a for 24 hours and
then mRNA was extracted and evaluated for gene expressions
of FLG, LOR, and IVL. The gene expression of FLG, LOR, and
IVL was significantly inhibited in the KCs treated with Th2
cytokines (FLG: 0.57±0.04 ng; LOR: 0.72±0.09 ng; IVL:
6.95±1.52 ng) compared with the untreated KCs (FLG:
2.61±0.09 ng; LOR: 3.22±0.31 ng; IVL: 16.95±1.23 ng;
Po0.01 for all comparisons; Figure 3a–c). In contrast, the
gene expression of FLG and LOR was significantly inhibited
in the KCs treated with TNF-a (FLG: 1.22±0.06 ng,
Po0.001; LOR: 0.95±0.08 ng, Po0.05) compared with the
untreated KCs (FLG: 2.61±0.09 ng; LOR: 3.22±0.31 ng;
Figure 3a and b). However, TNF-a did not affect IVL
expression (Figure 3c), suggesting that TNF-a modulates
barrier proteins in a manner different than Th2 cytokines.
In addition, we determined the effects of TNF-a and Th2
cytokines on human b-defensin 2 (HBD-2), a potent
antimicrobial peptide in the epidermis. We found that
HBD-2 expression was significantly increased in the KCs
treated with TNF-a (1.89±0.21 ng HBD-2 per ng of GAPDH;
Po0.001), compared with the untreated KCs (0.36±0.07 ng),
whereas Th2 cytokines did not induce HBD-2 (Figure 3d).
This suggests that TNF-a potentially induces antimicrobial
peptides as well as inhibits barrier proteins in KCs.
c-Jun N-terminal kinase inhibitor blocks TNF-a-mediated
inhibition of FLG and LOR
As NF-kB is a downstream target of TNF-a (Hsu et al., 1995;
Clarke et al., 2010), we treated primary KCs with NF-kB
inhibitor (10 nM) before TNF-a stimulation to examine
whether NF-kB inhibitor blocks the effect of TNF-a on barrier
proteins. NF-kB inhibitor did not block the TNF-a effects on
gene expression of FLG (Figure 4a) and LOR (data not
shown), suggesting that TNF-a does not downregulate FLG
and LOR by activating NF-kB.
It is known that TNF-a also activates the mitogen-activated
protein kinase pathway (Chang and Karin, 2001; Lin, 2003;
Zarubin and Han, 2005). Therefore, we pre-treated primary
KCs with an extracellular signal-regulated kinases 1/2
inhibitor (5 mM), p38 inhibitor (5 mM), and sp600125 (c-Jun
N-terminal kinase inhibitor, 1 mM) before TNF-a (20 ngml1)
stimulation. Extracellular signal-regulated kinases 1/2 inhibi-
tor and p38 inhibitor did not block the TNF-a effects on gene
expression of FLG (Figure 4b and c) and LOR (data not
shown). However, FLG gene expression was not significantly
decreased in the KCs pre-treated with sp600125
(2.71±0.14 ng FLG per ng of GAPDH; Po0.001), as
compared with untreated KCs (1.20±0.06 ng; Figure 4d).
Similarly, LOR gene expression was not significantly
decreased in the KCs pre-treated with sp600125, as
compared with the untreated KCs (data not shown), whereas
IVL gene expression was not affected by TNF-a or sp600125
(data not shown).
TNF-a antagonist upregulates FLG and LOR
On the basis of our observations that TNF-a inhibits the
in vitro expression of FLG and LOR, we further investigated
the clinical significance of this observation by determining
whether a TNF-amonoclonal Ab (etanercept) could block the
TNF-a-mediated inhibition of these barrier proteins in vivo in
humans with psoriasis. For this study, six independent
psoriasis patients followed up at the Rockefeller University
were given 50mg etanercept, bi-weekly for 12 weeks. We
studied skin biopsies, before and after they received
etanercept. The gene expression of FLG was significantly
increased in lesional skin from after treatment
(23.89±5.78 ng FLG per ng of GAPDH; Po0.05) compared
with lesional skin from before treatment (4.38±1.77 ng;
Figure 5a). Similarly, LOR gene expression was significantly
increased in lesional skin from after treatment
(27.95±6.92 ng LOR per ng GAPDH; Po0.01) compared
with lesional skin from before treatment (4.54±1.43 ng;
Figure 5b). Interestingly, the increase in gene expression of
FLG and LOR is positively correlated with change in psoriasis
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Figure 2. Tumor necrosis factor-a (TNF-a) inhibits expression of filaggrin (FLG). Primary human keratinocytes (KCs) were stimulated in the presence
of various concentrations of TNF-a for 24 hours. The gene expression of FLG was examined by real-time RT-PCR (a). In addition, primary human KCs were
pre-incubated with 0.1 mgml1 of TNF-a-neutralizing antibody before TNF-a (20 ngml1) stimulation. The gene expression of FLG was then examined by
real-time RT-PCR (b). *Po0.05; **Po0.01; ***Po0.001. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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area and severity index (data not shown). However, IVL gene
expression was not affected (Figure 5c). In addition, we also
examined the gene expression of FLG and LOR in lesional
and non-lesional psoriasis skin from before treatment. The
gene expression of FLG and LOR in lesional psoriasis skin
was significantly decreased compared with non-lesional
psoriasis skin (FLG: Po0.05; LOR: Po0.01; Figure 5a and b).
Interestingly, the gene expression of TNF-a in lesional
psoriasis skin was significantly increased compared with
non-lesional psoriasis skin (Po0.05; data not shown).
Immunostaining confirmed increased expression of both
FLG and LOR in skin after treatment, as compared with skin
from before treatment (Figure 6a and b). The composite data
in all samples are shown in Figure 6c and d. The mean
fluorescent intensity of FLG and LOR was significantly
increased in lesional skin from after treatment compared
with lesional skin from before treatment (FLG: Po0.01; LOR:
Po0.01). However, the mean fluorescent intensity of IVL was
not affected (data not shown). In addition, the mean
fluorescent intensity of LOR in lesional psoriasis skin was
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Figure 3. The effects of tumor necrosis factor-a (TNF-a) and Th2 cytokines on barrier proteins. Primary human keratinocytes were stimulated with
TNF-a (20 ngml1) or a combination of IL-4 (50 ngml1) and IL-13 (50 ngml1) for 24 hours. The gene expression of filaggrin (FLG) (a), loricrin (LOR) (b),
involucrin (IVL) (c), and human-b defensin 2 (HBD-2) (d) were examined by real-time RT-PCR. **Po0.01; ***Po0.001. GAPDH, glyceraldehyde-3-phosphate
dehydrogenase.
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significantly decreased compared with non-lesional psoriasis
skin (Po0.05).
DISCUSSION
In our current study, we demonstrated that there is a
deficiency of FLG and LOR in lesional and non-lesional
psoriasis skin. IVL expression, however, was not decreased in
psoriasis skin. We demonstrated these findings using both
real-time RT-PCR and immunostaining. This finding is similar
to our previous data showing a relative decrease of FLG and
LOR in psoriasis skin in comparison with normal skin
(Guttman-Yassky et al., 2009). Therefore, our data suggest
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that the well-established skin barrier defect (Huffmeier et al.,
2007; Proksch et al., 2008), known to occur in psoriasis, is
the result of a deficiency in epidermal barrier proteins. In
contrast, it is well known that psoriasis is rarely associated
with microbial infection and overexpress antimicrobial
peptides. Therefore, this skin disease has a different profile
of epidermal barrier proteins than found in atopic dermatitis
(AD; Ong et al., 2002).
KCs are the primary cells of the epidermis and express skin
barrier proteins including FLG, LOR, and IVL (Watt, 1989;
Candi et al., 2005). For this reason, we used primary human
KCs to examine why FLG and LOR are decreased in the skin
of psoriasis patients. Psoriasis skin is characterized by
overexpression of TNF-a (Kristensen et al., 1993; Ettehadi
et al., 1994). Therefore, we investigated whether skin barrier
proteins are modulated by TNF-a. We found that the gene
expression of FLG and LOR was significantly inhibited in the
KCs treated with TNF-a following a dose-dependent pattern.
The importance of TNF-a in downregulating these barrier
proteins was supported by the observation that a TNF-a-
neutralizing Ab blocked the in vitro TNF-a-mediated inhibi-
tion of FLG and LOR.
It has been reported that o5% of patients with psoriasis
have FLG mutations and 80% of psoriasis patients have FLG
deficiency in their skin (Huffmeier et al., 2007). Our
current data suggest that the deficiency of FLG and LOR in
most patients with psoriasis is acquired as the TNF-a
modulation. In addition, our laboratory has previously
demonstrated that deficiencies of barrier proteins in AD skin
are acquired rather than constitutive (Howell et al., 2007;
Kim et al., 2008).
On the basis of our current data and previous data (Howell
et al., 2007; Kim et al., 2008), both TNF-a and Th2 cytokines
modulate barrier proteins. To determine whether the me-
chanisms for cytokine modulation of epidermal proteins are
different, we stimulated KCs with TNF-a or Th2 cytokines and
examined the effects of these cytokines on barrier proteins.
Interestingly, TNF-a only reduced FLG and LOR. In contrast,
Th2 cytokines inhibited FLG, LOR, and IVL. Therefore, we
could suggest that TNF-a modulates barrier proteins in a
manner different than Th2 cytokines. Indeed previous reports
have demonstrated that Th2 cytokines inhibit barrier proteins
via the signal transducer and activator of transcription 6
in vitro in KCs and in vivo in mice that overexpress signal
transducer and activator of transcription 6 (Kim et al., 2008;
Sehra et al., 2010).
Both AD and psoriasis are common chronic inflammatory
skin diseases and are characterized by impaired barrier
proteins. Importantly, 30% of AD patients suffer from
recurrent skin infections, whereas only 6.7% of psoriasis
patients suffer from skin infection (Christophers and Henseler,
1987). To explain this discrepancy, we examined the
expression of HBD-2, a potent antimicrobial peptide, in the
KCs treated with TNF-a or Th2 cytokines, which are
overexpressed in AD skin. Importantly, HBD-2 was increased
by TNF-a; however, Th2 cytokines did not increase HBD-2.
Therefore, we postulate that the reason psoriasis patients
have a barrier defect, but are less susceptible to microbial
infections, than AD patients is that TNF-a only inhibits barrier
proteins while inducing antimicrobial peptides. Indeed our
laboratory has previously demonstrated that TNF-a induces
HBD-2 through signal transducer and activator of transcrip-
tion 1 and NF-kB (Albanesi et al, 2007). Furthermore, our
data recently showed that TNF-a synergizes with IL-17 in
induction of antimicrobial peptides in human KCs (Chiricozzi
et al, 2010). In contrast, in AD, Th2 cytokines inhibit both
barrier proteins and antimicrobial peptides needed to fight
infection.
Because TNF-a activates NF-kB (Hsu et al., 1995; Clarke
et al., 2010) and mitogen-activated protein kinase (Chang
and Karin, 2001; Lin, 2003), we further investigated the effect
of a NF-kB inhibitor or mitogen-activated protein kinase
inhibitors on TNF-a modulation of barrier proteins. Of note,
only the c-Jun N-terminal kinase inhibitor blocked the TNF-a-
mediated inhibition of FLG and LOR in the KCs. This
observation strongly suggests that TNF-a modulates the
expression of FLG and LOR through the c-Jun N-terminal
kinase-dependent pathway.
Perhaps, the most important observation made in our
current study was to examine the role of TNF antagonism
in vivo on skin barrier protein expression in the skin of
patients with psoriasis. Treatment of patients with psoriasis
for 12 weeks with anti-TNF-a significantly increased the
expression of FLG and LOR in their psoriasis lesions.
Therefore, our data strongly suggest that TNF-a antagonists
contribute to clinical improvement in patients with psoriasis
by improving barrier protein expression. We also demon-
strate directly in a clinically relevant setting that TNF-a
has a key role in driving barrier dysfunction in psoriasis.
We conclude that barrier protein deficiency in patients
with psoriasis can be acquired via TNF-a-mediated down-
regulation.
MATERIALS AND METHODS
Subjects
Subjects included 10 healthy persons with no history of skin disease
and 10 psoriasis patients with moderate-to-severe psoriasis. In
addition, we studied skin biopsies from six adult psoriasis patients
with moderate-to-severe psoriasis (mean psoriasis area and severity
index: 25.9±4.4) who received 12 weeks of the anti-TNF-a
etanercept therapy in vivo under a Rockefeller University Institu-
tional Review Board-approved protocol. Skin biopsies (6mm) were
obtained from lesional and non-lesional skin of these patients before
etanercept therapy was initiated and after 12 weeks of treatment. The
patients were treated with 50mg of etanercept, bi-weekly, as
previously described (Zaba et al., 2007). Overall, a 69% decrease
in psoriasis area and severity index in all study participants was
observed with etanercept therapy, as previously described (Zaba
et al., 2007, 2009). None of the patients had previously received
systemic corticosteroids or cyclosporine, and none had received
topical corticosteroid or calcineurin inhibitors for at least 1 week
before enrollment. These studies were conducted according to the
Declaration of the Helsinki Guidelines and were approved by the
institutional review board at the National Jewish Health in Denver.
All subjects gave written informed consent before participation in
these studies.
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From all other normal subjects and patients with lesional and
non-lesional psoriasis, 2mm punch skin biopsies were obtained. The
skin biopsies were immediately submerged in 1ml Tri Reagent
(Molecular Research Center, Cincinnati, OH) and frozen at 80 1C
for future RNA isolation and immunostaining, or in 1ml of 10%
buffered formalin for immunohistochemistry.
RNA preparation and real-time RT-PCR
Total RNA was isolated from skin biopsies by chloroform/phenol
extraction and isopropanol precipitation according to manufac-
turer’s guidelines (Sigma Chemical, St Louis, MO). RNeasy Mini Kits
(Qiagen, Valencia, CA) were used according to the manufacturer’s
protocol to isolate RNA from cell cultures and to further purify RNA
from skin biopsies. RNA was reverse transcribed into cDNA and
analyzed by real-time RT-PCR by using an ABI Prism 7000 sequence
detector (Applied Biosystems, Foster City, CA) described earlier
(Nomura et al., 2003). Primers and probes for human GAPDH, FLG,
LOR, IVL, and HBD-2 were purchased from Applied Biosystems. To
allow for comparisons between samples and group, quantities of all
targets in test samples were normalized to the corresponding
GAPDH levels in the skin biopsies and cultured KCs, and expressed
as target gene normalized to GAPDH.
Immunohistochemical staining
Paraffin-embedded tissues were cut at 5mm and placed on frosted
microscope slides. Using toluene and a series of ethanol washes slides
were deparaffinized and rehydrated. Slides were incubated with a
monoclonal mouse anti-human Ab directed against FLG (1:500
dilution; Abcam, Cambridge, MA) or a polyclonal rabbit anti-human
Ab direct against LOR (1:500 dilution; Abcam) at 4 1C overnight. The
cell and tissue staining kits (R&D systems, Minneapolis, MN) were
used according to the manufacturer’s protocol. Ab specificity was
determined by replacing the primary Ab with an isotype-matched
control (purified non-immune mouse IgG or rabbit IgG; Southern
Biotechnology, Birmingham, AL). All slides were coded before the
samples were evaluated so that the identity of the study subjects was
not revealed. Images were collected at  400 magnification and the
intensity of the immunostaining was scored on a scale from 0 to 5,
with 0 indicating no staining and 5 the most intense staining.
Immunofluorescent staining
Frozen tissues from six patients were cut at 5mm and fixed in 4%
paraformaldehyde for 10minutes at room temperature. Skin sections
were then blocked as described above. Slides were then stained with
a monoclonal mouse anti-human Ab directed against FLG (1:500
dilution; Abcam), a polyclonal rabbit anti-human Ab direct against
LOR (1:500 dilution; Abcam), and a monoclonal mouse anti-human
Ab directed against IVL (1:500 dilution; Abcam) at 4 1C overnight.
Slides were then washed with phosphate-buffered saline/Tween
(0.1%), followed by incubation with a Cy3-conjugated donkey anti-
mouse IgG (Jackson Laboratories, West Grove, PA) or a Cy3-
conjugated donkey anti-rabbit IgG (Jackson Laboratories). The slides
were visualized with confocal microscopy (Leica, Wetzlar, Germany).
Slides were coded to ensure patient anonymity. Images were collected
at  40, and levels of mean fluorescence intensity were measured with
Slidebook 5.0 (Intelligent Imaging Innovations, Denver, CO). Mean
fluorescence intensity was determined for each exposure group and
was reported as mean mean fluorescence intensity±SE.
KC cell culture
Primary human KCs were grown in serum-free EpiLife cell culture
medium (Cascade Biologics, Portland, OR) containing 0.06mmol l1
calcium chloride, 1% human KCs growth supplement V2 (Cascade
Biologics), and 1% antibiotics (penicillin/streptomycin) under
standard tissue culture conditions. To investigate the effects of the
TNF-a on barrier proteins, primary KCs were differentiated with
1.3mmol l1 CaCl2 for 5 days and then incubated in various
concentrations of TNF-a (R&D systems) for 24 hours. To further
examine the modulation of TNF-a on barrier proteins, KCs were
stimulated in the presence and absence of TNF-a (20 ngml1), anti-
TNF-a (0.1 mgml1, R&D systems), NF-kB activation inhibitor
(10 nM, EMD Chemicals, Darmstadt, Germany), IL-4 and IL-13
(50 ngml1, R&D systems), or their combination for 24 hours. In
addition, the primary KCs were stimulated with TNF-a in the
presence or absence of mitogen-activated protein kinase inhibitors
(EMD Chemicals), including extracellular signal-regulated kinases
1/2 inhibitor (5 mM), p38 inhibitor (5mM), and c-Jun N-terminal kinase
inhibitor (1 mM). Total RNA was isolated from KCs by using RNeasy
kits according to the manufacturers guidelines (Qiagen) for real-time
RT-PCR.
Statistical analysis
Statistical analysis was conducted using Graph Pad Prism, version
4.03 (San Diego, CA). Statistical differences in gene expression or
protein staining between multiple groups was determined by using
one-way analysis of variance, and significant differences were
determined by a Tukey–Kramer test.
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